Please ensure Javascript is enabled for purposes of website accessibility
Contact us Contact Us
EN
Home > Featured Products > Oncology Research > Breast Cancer
Breast Cancer Research Reagents — HER2, ER, PR, TROP2 | abinScience

Breast Cancer Research Reagents

Breast cancer is the most commonly diagnosed cancer globally. Molecular subtyping — Luminal A/B, HER2-enriched, and triple-negative (TNBC) — dictates treatment strategy and prognosis. abinScience offers validated reagents targeting HER2/ErbB2, ER, PR, BRCA, Ki-67, TROP2, Nectin-4, and emerging ADC targets for breast cancer biomarker discovery and translational research. RUO

Key Biomarkers & Targets

HER2 / ErbB2
CD340 / ERBB2
Overexpressed in ~20% of breast cancers. Therapeutic target for trastuzumab, pertuzumab, T-DXd. 100+ antibodies and biosimilar-grade proteins.
Antibodies • Proteins • Biosimilars
ERα / ESR1
Estrogen Receptor alpha
Expressed in ~75% of breast cancers; primary determinant for endocrine therapy eligibility. Antibodies with IHC validation available.
Antibodies
PR / PGR
Progesterone Receptor
Co-assessed with ER for luminal subtype classification. Antibodies available for research use.
Antibodies
TROP2
TACSTD2
Overexpressed in TNBC; validated ADC target (sacituzumab govitecan). 29 antibodies and recombinant proteins for ADC target research.
Antibodies • Proteins • Biosimilars
Nectin-4
PVRL4
Emerging ADC target in breast and urothelial cancers (enfortumab vedotin). 21 detection antibodies and recombinant proteins.
Antibodies • Proteins
Ki-67 / MKI67
Proliferation Marker
Distinguishes Luminal A (low Ki-67) from Luminal B (high Ki-67). Antibodies available for research use.
Antibodies

Why Researchers Choose abinScience for Breast Cancer

Full Subtyping Panel ER, PR, HER2, Ki-67 antibodies for the four-marker IHC panel used in clinical breast cancer molecular classification.
ADC Target Profiling TROP2, Nectin-4, HER2, and emerging targets (HER3, FRα, CDH6) — recombinant proteins and antibodies for antibody–drug conjugate discovery.
TNBC Immune Microenvironment PD-L1, CTLA-4, and TIL-associated markers for characterizing the immunosuppressive tumor microenvironment in triple-negative breast cancer.
Biosimilar Comparability Research-grade trastuzumab, pertuzumab, and T-DXd reference proteins for biosimilar analytical similarity and potency testing.
Original Manufacturer Pricing Direct-from-manufacturer pricing with no distributor markup. Bulk and custom conjugation options available.

Common Research Applications

  1. Molecular subtyping by IHC: Classify breast tumors as Luminal A, Luminal B, HER2-enriched, or TNBC using our ER/PR/HER2/Ki-67 antibody panel on FFPE tissue sections.
  2. HER2-targeted therapy development: Research-grade HER2 biosimilar proteins available with ELISA, FACS, and Functional assay validation for comparability studies.
  3. ADC target validation: Anti-TROP2 antibodies with FCM validation and anti-Nectin-4 antibodies with FCM/ELISA validation available for ADC target expression profiling.
  4. CDK4/6 pathway analysis: CDK4, CDK6, and related pathway antibodies available for studying resistance mechanisms to CDK4/6 inhibitors in ER+ breast cancer.

Documents & QC Data

Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQs

Which antibodies are recommended for HER2 IHC scoring?

Yes — clone 1A064 with ELISA, IHC, and WB validation (Human). Research-grade HER2 biosimilar proteins (e.g., disitamab, trastuzumab) also available. Research use only.

Do you carry ER/ESR1 antibodies?

Yes. Anti-ESR1/ERα polyclonal antibodies with ELISA, IHC, and WB validation (Human/Mouse/Rat). Monoclonal clones (e.g., RB125) with ELISA and IF validation also available.

What reagents do you recommend for TNBC research?

For TNBC, we offer: PD-L1 antibodies (IHC/WB/FC validated), TROP2 antibodies (FC validated), Nectin-4 antibodies (FC/ELISA validated), CTLA-4 antibodies (IHC/WB validated), and EGFR antibodies (IHC/WB validated).

Can I use your TROP2 antibodies for ADC target expression research studies?

Anti-TROP2/TACSTD2 monoclonal antibodies with FC validation (e.g., clones TP15-4, SAA0113). Research-grade biosimilar proteins (sacituzumab, datopotamab) and recombinant TROP2 proteins (His/Fc-tagged) also available.

Do you offer custom antibody development for novel breast cancer targets?

Yes — our parent company AtaGenix provides full custom antibody services from immunogen design through hybridoma production, including targets not yet in our catalog.

361 product results for "Breast Cancer"

Options+
Options
Confirm
  • Product types
    0 selected
    Proteins (50)
    Research Biosimiliar (9)
    Stable Cell Lines (5)
    Assay Kit (1)
    Research Biosimilar (124)
    Biosimilars (1)
    Antibodies (171)
  • Expression system
    0 selected
    E. coli (31)
    HEK293T (5)
    Mammalian Cells (138)
  • Target
    0 selected
    4-1BB & FAP (1)
    AKT1 (5)
    BRCA1 (1)
    BRCC3 (1)
    AKT3 (1)
    FZR1 (1)
    ERBB3/HER3 (33)
    CD137/4-1BB & CD340/ERBB2 (2)
    CD340/ERBB2 (90)
    CD221/IGF1R & ERBB3/HER3 (1)
    TOP2A (4)
    ERBB2 / HER2 / CD340 & CD137/4-1BB/TNFRSF9 (1)
    4-1BB & HER2 (1)
    Ki67/MKI67 (3)
    CD340/ERBB2 & CD279/PD-1 (1)
    BCCIP (1)
    TACSTD2/TROP2 (33)
    PGR (2)
    TROP2/TACSTD2/TROP-2 (1)
    HLA-A2-peptide (LLLTVLTVV) Complex (2)
    CD144/CDH5 (2)
    CDK6 (2)
    EGFR/ERBB1 & ERBB3/HER3 (1)
    NECTIN4/PVRL4 (30)
    PHF11 (1)
    ESR2/ER-beta (4)
    PTEN (2)
    GATA3 (5)
    PA2G4 (1)
    CD172a/SIRPA & CD340/ERBB2 (1)
    PIK3CA (2)
    CD340/ERBB2/HER2 & CD3E (1)
    CD324/CDH1 (16)
    BABAM2 (1)
    TACSTD2/TROP2 & HSG (1)
    CDH1/CDH11 (5)
    CD340/ERBB2/HER2&CD314/KLRK1/NKG2D (1)
    PIP (4)
    CD340/ERBB2 & CD3 (1)
    HER2 (domain III) (1)
    CCND1 (2)
    ERBIN (2)
    ABRAXAS1 (1)
    p-AKT1 (3)
    Pan-AKT (1)
    CD340/ERBB2 & CD3E (5)
    HMG20B (1)
    CDK4 (2)
    ESR1/ER-alpha (6)
    CD340/ERBB2/HER2 (6)
    BRCA2 (2)
    CD227/MUC1 (53)
    PINK1 (4)
    AKT2 (1)
    CD340/ERBB2 & ERBB3/HER3 (1)
  • Species
    0 selected
    Mus musculus (Mouse) (6)
    Human (169)
    Homo sapiens (Human) (2)
    Mouse (2)
    Zebrafish (1)
    Dog (4)
  • Applications
    0 selected
    IP (5)
    IHC-P (1)
    Bioactivity: FACS (1)
    ELISA (286)
    Blocking (1)
    SDS-PAGE (50)
    Research in vivo (1)
    IHC (57)
    Bioactivity: FACS (123)
    Immunogen (50)
    WB (119)
    Functional assay (124)
    Bioactivity testing in progress (41)
    FuncS (2)
    FCM (96)
    Research in vivo (124)
    Neutralization (2)
    ICC (6)
    FACS (11)
    Functional assay (12)
    IF (13)
  • Reactivity
    0 selected
    Pig (2)
    Pongo pygmaeus (1)
    Ovis aries (2)
    Cat (1)
    NECTIN4/PVRL4 (1)
    Taeniopygia guttata (1)
    Symphalangus syndactylus (1)
    AKT8 murine leukemia virus (2)
    Anolis carolinensis (1)
    Mouse (24)
    Mus musculus (1)
    Dog (3)
    Xenopus laevis (2)
    Aspidoscelis uniparens (1)
    Rat (19)
    Bovine (1)
    Callithrix jacchus (1)
    Rattus norvegicus (1)
    Pongo abelii (2)
    Bos taurus (5)
    Equus caballus (1)
    Hylobates lar (1)
    Homo sapiens (1)
    Human (160)
    Chicken (2)
    Gorilla gorilla gorilla (1)
    Macaca mulatta (2)
    Hylobates agilis (1)
    Homo sapiens (Human) (3)
    Mesocricetus auratus (1)
    Pan troglodytes (1)
  • Host species
    0 selected
    Alpaca (3)
    Humanized (22)
    Mouse (75)
    Chimeric (3)
    Human (157)
    Rabbit (35)
    HEK293T (5)
    Rat (2)
  • Clonality
    0 selected
    Monoclonal (268)
    Polyclonal (35)
  • Conjugate
    0 selected
    FITC (19)
    APC (19)
    PerCP (19)
    PE (19)
    Unconjugated (199)

Quick access

Contact Us

  • +86-27-65523339

  • info@abinscience.com

  • Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China

  • linkedin
  • Ins
  • youtube
  • youtube
Copyright © 2026 abinScience. All Rights Reserved. All Products are for Research Use Only